Pall Corporation, a global leader in filtration, separation and purification, is pleased to announce the following new additions to the Allegro single-use chromatography and CadenceTM continuous bioprocessing product portfolios.

Each product enables scalable process integration and intensification for biopharmaceutical manufacturers, while drastically reducing resource use, process time, user risk and overall facility footprint. The technologies will be showcased this week at the BPI 2017 event in Boston, MA. 

"A changing market has increased demand for drug manufacturers to innovate, thereby driving the need for critical automated end-to-end traditional and single-use process solutions. This is especially true as many manufacturers look to pursue the advantages of semi- or fully-continuous bioprocessing approaches," explained Martin Smith, Pall Chief Technology Officer. "The latest additions to our technology portfolio provide the support manufacturers need and carry forward Pall's promise to bring continuous bioprocesses to life. We are happy to introduce these new technologies to the industry during BPI 2017 this week."